Syndax Pharmaceuticals Inc (NASDAQ: SNDX)

Syndax Pharmaceuticals Inc is a commercial stage biopharmaceutical company engaged in the discovery development and commercialization of innovative cancer therapies. The company markets two FDA approved products, Revuforj (revumenib) for the treatment of relapsed or refractory acute leukemia with KMT2A translocation or NPM1 mutation and Niktimvo (axatilimab csfr) for chronic graft versus host disease after failure of at least two prior systemic therapies. Revuforj received its first FDA approval in November 2024 for KMT2A rearranged acute leukemia and a second approval in October 2025 for NPM1 mutated acute myeloid leukemia. Niktimvo obtained FDA approval in August 2024 based on the AGAVE 201 trial showing durable responses in patients with refractory chronic graft versus host disease. Beyond these approved therapies, Syndax advances clinical programs exploring revumenib in combination regimens for newly diagnosed leukemia, myelofibrosis and other solid tumors, while investigating axatilimab for early stage chronic graft versus host disease and idiopathic pulmonary fibrosis.

Revenue is generated primarily from product sales of Revuforj and Niktimvo in the United States where the company co commercializes Niktimvo with Incyte and retains full commercial rights to Revuforj. The partnership with Incyte provides profit sharing on US sales and entitles Syndax to receive royalties on sales outside the United States according to the collaboration agreement. In addition to product sales, Syndax has received upfront and milestone payments from its collaborations, including a non refundable cash payment of 117 million dollars from Incyte in 2021 and an upfront fee of 350 million dollars from Royalty Pharma in 2024 for the purchase of certain revenue streams. Royalty Pharma is entitled to a percentage of net sales of Niktimvo in the United States subject to a cap of 822.5 million dollars in aggregate payments. The company also earns royalty income from licensing agreements with entities such as Eddingpharm for development of entinostat in China and other Asian markets.

Syndax occupies a distinctive niche as a first in class developer of menin and CSF 1R inhibitors with Revuforj representing the only approved agent targeting the menin KMT2A interaction for acute leukemia. The menin inhibitor landscape includes competing agents such as Kobzifti (ziftomenib) which is approved only for adult NPM1 mutated AML and several preclinical candidates, giving Syndax a first mover advantage in the broader leukemia market. In the myelofibrosis space, current standard of care relies on JAK inhibitors such as ruxolitinib and fedratinib which reduce symptoms but do not significantly reverse bone marrow fibrosis, presenting an opportunity for Syndax to investigate menin inhibition to modify disease pathology. For chronic graft versus host disease, existing FDA approved therapies include ibrutinib, ruxolitinib and belomosodil which act primarily on T and B cells, whereas Syndax axatilimab targets monocyte derived macrophages to address the fibrotic component of the disease. This mechanistic differentiation may allow Syndax to achieve deeper and more durable responses in patients with fibrotic complications.

The company serves hospitals, academic medical centers, oncology clinics and transplant centers that treat patients with relapsed or refractory acute leukemia, chronic graft versus host disease and myelofibrosis. These providers rely on Syndax products to address unmet needs in patient populations with limited therapeutic options after failure of standard regimens. While specific customer names are not disclosed, the payer mix includes private insurers, government programs such as Medicare and Medicaid and managed care organizations that determine formulary coverage and reimbursement levels. Syndax also works with specialty pharmacy distributors and community oncology practices to ensure broad patient access to its therapies across the United States.